BCN HEALTH will present several communications at the EASL and AASLD congresses evaluating... 27/05/2024 Healthcare Rare diseases The consulting firm specialized in the health sector will compare different quantitative data between patients suffering... Partners - BCN Health
Oryzon reports financial results and corporate update for quarter ended March 31, 2024 07/05/2024 Healthcare Access to innovation Rare diseases Personalized medicine Advanced therapies Financing Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD)... Partners - Oryzon Genomics
Mikrobiomik launches strategic investment round to advance its first medicine based on the... 30/04/2024 Healthcare Drug discovery Rare diseases Innovative drugs The Biscayan biopharmaceutical company, which plans to launch its first biological medicine into the market in the first... Partners - Mikrobiomik
BCN HEALTH publishes a study evaluating the hospital incidence and medical costs of congen... 22/04/2024 Healthcare Rare diseases BCN HEALTH has published the study ‘Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter... Partners - BCN Health
Biotechnology lays the groundwork for the present and future of healthcare and drives the ... 07/04/2024 Healthcare Drug discovery Rare diseases Personalized medicine Advanced therapies Antibiotic resistance Climate change Agrifood Animal health The health pipeline of AseBio includes 130 molecules for 150 indications being investigated by 40 national companies... AseBio
Biotechnology lays the groundwork for the present and future of healthcare and drives the ... 07/04/2024 AseBio's health pipeline includes 130 molecules for 150 indications being researched by 40 national companies, with... AseBio
The Spanish AI Healthcare Landscape 04/04/2024 Healthcare Access to innovation Rare diseases Personalized medicine While not yet a global player, Artificial Intelligence (AI) is increasingly being integrated into the healthcare... Partners - OWKIN
The Role of Real-World Evidence in the Price and Reimbursement Decisions for Rare Diseases... 02/04/2024 Healthcare Rare diseases Innovative drugs Financing Real-world evidence (RWE) is a promising source of data that could help to accelerate drug access in rare diseases. Partners
Almirall signs licensing agreement with Eloxx Pharmaceuticals and enters the field of rare... 25/03/2024 Healthcare Access to innovation Rare diseases Personalized medicine Advanced therapies The Spanish pharmaceutical company has obtained global rights to develop and commercialize the drug ZKN-013. Partners - Almirall
Sustainable agriculture, new food sources, protection against infectious diseases or waste... 26/03/2024 Healthcare Biosimilars Rare diseases Climate change Agrifood Food & feed Agriculture Biotechnology provides solutions through plant genetic engineering, the revaluation of food industry by-products, new... AseBio
